MC10 Announces the Use of BioStamp nPoint® in Phase III Study of Huntington Disease

LEXINGTON, Mass.--()--MC10, Inc., the developer of BioStamp nPoint®, an end-to-end system for physiological data collection and analytics, announced today that the BioStamp nPoint system will be utilized to collect and assess movement activity data in a new Phase III study evaluating a potential treatment for chorea associated with Huntington disease, a hereditary neurodegenerative disease. The study is sponsored by Neurocrine Biosciences and conducted in collaboration with the Huntington Study Group.

In a subset of 50 study participants, BioStamp nPoint will track activity, sleep and posture, and investigate exploratory measurements of gait disturbances and truncal chorea, which are involuntary movement symptoms of Huntington disease. The use of BioStamp nPoint to collect objective measures of Huntington disease represents a potential shift from the currently used subjective measures, including the Unified Huntington Disease Rating Scale (UHDRS) and other survey-based assessments.

MC10 has been collecting and analyzing important data in neurological diseases for years. These efforts have led to numerous publications, including many from collaborations with academic institutions, to expand the central nervous system (CNS) applicability of the physiological data provided by the system. The results of MC10’s ongoing academic collaborations will be instrumental in future developments of disease-specific endpoints and overall understanding of CNS diseases.

“We are excited about the continued use of our system in CNS studies, especially in partnership with Neurocrine Biosciences, a leader in advancing the treatment of movement disorders,” said Arthur Combs M.D., Chief Medical Officer of MC10. “Huntington disease impacts various aspects of a person’s life, and the ability to collect objective data on activity, sleep, posture, and involuntary movements on a 24-7 basis promises to provide new context to improve our overall understanding of the disease and associated symptoms and help advance treatment options.”

Dr. Combs spoke on the impact of continuous, real-world data collection at the Huntington Study Group’s Annual Meeting on November 8 in Sacramento.

About MC10
MC10 is a privately held company focused on improving human health through digital solutions. The company combines conformal BioStamp sensors with clinical analytics to unlock novel insights from physiological data collected from the home or in clinical settings. Our flagship product, BioStamp nPoint, is marketed into the clinical research community. MC10 is headquartered in Lexington, MA. Visit MC10 online at mc10inc.com or follow us on LinkedIn.

MC10®, BioStamp nPoint®, and the MC10 logo are registered marks owned by MC10, Inc.

Contacts

Katie Nolan
press@mc10inc.com
(857) 214-5671

Contacts

Katie Nolan
press@mc10inc.com
(857) 214-5671